Mantle Cell Lymphoma Care From Diagnosis Through Relapse: Expert Guidance on Applying the Latest Evidence

Explore key issues in the management of MCL in this comprehensive program designed to keep you abreast of rapidly evolving treatment strategies. Gain insights on new developments as they emerge with the CME-certified interactive module, downloadable slideset, short expert commentaries, and an Interactive Decision Support Tool that lets you compare your treatment choices for MCL patient scenarios you enter with those of 5 experts.
Christopher R. Flowers, MD, MS
Julie M. Vose, MD, MBA

ClinicalThought: MCL Management

Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Julie M. Vose, MD, MBA Released: April 30, 2018

Ibrutinib and acalabrutinib are both active in relapsed MCL. Read how I consider safety, long-term data, and patient preferences when deciding between these BTK inhibitors.

Christopher R. Flowers, MD, MS Released: August 10, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Pharmacyclics Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue